• Home
  • About
    • Our Constitution
    • Chairman’s words
    • Chairman and Board Members
  • Members
    • Become a Member
  • Annual Meetings
    • 1st Annual Meeting – 2010
    • 2nd Annual Meeting – 2011
    • 3rd Annual Meeting – 2012
    • 4th Annual Meeting -2013
    • 5th Annual Meeting- 2014
    • 7th Annual Meeting -2016
    • 8th Annual Meeting -2017
    • 9th Annual Meeting -2018
    • 10th Annual Meeting
    • 11th Annual Meeting
    • 12th Annual Meeting
  • Abstracts
    • Abstracts 2010
    • Abstracts 2011
    • Abstracts 2012
    • Abstracts 2014
    • Abstracts 2015
    • Abstracts 2016
    • Abstracts 2017
    • Abstracts 2018
    • Full Abstract List
  • Organizations
    • ISMFM
    • Israel Medical Association
    • Placenta – The Official Jourmal of IFPA
    • The Israel Fertility Association
    • SMFM
    • International Federation of Placenta Associations
    • The Endocrine Society of Australia
    • Nano Science
    • The Society for Reproductive Biology
    • Australasian Diabetes in Pregnancy Society
    • Society of Theriogenology
    • American College of Theriogenologists
    • The Fetal Medicine Foundation
  • Contact
Menu
  • Home
  • About
    • Our Constitution
    • Chairman’s words
    • Chairman and Board Members
  • Members
    • Become a Member
  • Annual Meetings
    • 1st Annual Meeting – 2010
    • 2nd Annual Meeting – 2011
    • 3rd Annual Meeting – 2012
    • 4th Annual Meeting -2013
    • 5th Annual Meeting- 2014
    • 7th Annual Meeting -2016
    • 8th Annual Meeting -2017
    • 9th Annual Meeting -2018
    • 10th Annual Meeting
    • 11th Annual Meeting
    • 12th Annual Meeting
  • Abstracts
    • Abstracts 2010
    • Abstracts 2011
    • Abstracts 2012
    • Abstracts 2014
    • Abstracts 2015
    • Abstracts 2016
    • Abstracts 2017
    • Abstracts 2018
    • Full Abstract List
  • Organizations
    • ISMFM
    • Israel Medical Association
    • Placenta – The Official Jourmal of IFPA
    • The Israel Fertility Association
    • SMFM
    • International Federation of Placenta Associations
    • The Endocrine Society of Australia
    • Nano Science
    • The Society for Reproductive Biology
    • Australasian Diabetes in Pregnancy Society
    • Society of Theriogenology
    • American College of Theriogenologists
    • The Fetal Medicine Foundation
  • Contact
Facebook
CAN PLACENTAL VASCULAR LESIONS PREDICT RECCURENCE OF PREECLAMPSIA?
Home ‹ 2010 Abstracts ‹ CAN PLACENTAL VASCULAR LESIONS PREDICT RECCURENCE OF PREECLAMPSIA?

Eran Weiner, MD, Noa Rymer-Haskel, MD, Ehud Grinstein, MD, Ohad Feldstein, MD,  Yossi Mizrachi, MD, Letizia Schreiber, MD, Jacob Bar, MD, MSc,  Michal Kovo, MD, PhD

Department of Obstetrics & Gynecology, the Edith Wolfson Medical Center, Holon, Israel

Objective: To investigate the association between placental vascular lesions in an initial pregnancy with preeclampsia (PE), and recurrence of PE in subsequent pregnancies.

Materials and Methods – According to departmental protocol, during 2008-2014, placentas from every PE patients, were sent to histopathology examination.  PE was diagnosed according to ACOG criteria. This cohort of PE patients were followed for their subsequent pregnancy and were divided into those who developed recurrent PE in the subsequent pregnancy (Re-PE group) and those who did not developed recurrent PE (No Re-PE group). Maternal characteristics and placental pathology reports, of the initial pregnancies, were compared between the two groups. Placental lesions were classified to lesions of maternal vascular supply consistent with maternal malperfusion and lesions of fetal vascular supply consistent with fetal thrombo-occlusive disease. Multivariate logistic regression was used to control for potential known potential confounders for PE recurrence.

Results– Out of 372 PE patients, 94 included in the Re-PE group and 113 in the No Re-PE group. Maternal age and gestational age at delivery were similar between the Re-PE and the No Re-PE groups, 31±5.8vs. 31.3±6.0 years, respectively, p=0.3, and 35.9±2.7 vs. 36.4±2.9 weeks, respectively, p=0.204. Placentas from the Re-PE group had  higher rate of maternal vascular supply lesions and fetal vascular supply lesions, as compared to placentas from the No-PE group, 94.7% vs. 57.5%, respectively, p<0.001, and 57.4% vs. 16.8% respectively, p<0.001.

By logistic regression analysis, composite maternal and fetal vascular supply lesions were found to be independently associated with Re-PE, OR=15.2, 95% CI= 5.5-42.1, p<0.001, and OR=6.7, 95% CI= 3.4-13.1, p<0.001 respectively.

Conclusion –Placental maternal and fetal vascular lesions are independently associated with increased risk for recurrence of PE. In cases with preeclampsia, placental histopathology results should be used for patient counseling and prophylaxis considerations for their following pregnancies. 

Table-  aOR for the various placental vascular lesions for preeclampsia recurrence

    aOR 95% CI p-value
 

Maternal vascular supply lesions

Placental hemorrhage 2.04 0.6-6.9         0.247
Vascular lesions related to maternal malperfusion 2.1 1.1-3.9 0.016
Villous changes related to maternal malperfusion 3.8 2-7.1 <0.001
Composite maternal vascular supply lesions 15.2 5.5-42.1 <0.001
 

Fetal vascular supply lesions

Vascular lesions consistent with FTOD 3.6 1.5-8.5 <0.001
Villous lesions consistent with FTOD 6.1 2.6-14 <0.001
Composite fetal vascular supply lesions 6.7 3.4-13.1 <0.001
« Previous
Next »
Powered by Netmii and Art + Web
All rights reserved to ISPR -Israel Society for Placental Research
Scroll to top